Document is current

Article History

Received: 27 November 2024

Accepted: 19 May 2025

First Online: 2 June 2025

Declarations

:

: The project was listed in the record of processing activities for research projects in the Central Denmark Region (j.no. 1–16-02–313-21) and approved by the Ethics Committee in the Central Denmark Region (j. no: 1–10-72–246-21). All participants provided written informed consent.

: Not applicable.

: Seegene sponsors the Allplex HR HPV assays for the study. According to the contract between Seegene and the University Research Clinic for Cancer Screening and Dept. of Pathology, Randers Regional Hospital, Seegene had no influence on the scientific process and no editorial rights pertaining to this manuscript. The authors retained the right to submit the manuscript. MT and JSJ have participated in other studies with HPV test kits sponsored by Roche. MT has received honoraria fee from Roche Diagnostics and AstraZeneca for lectures on HPV self-sampling and HPV triage-methods, respectively. SVK was supported by a junior postdoctoral fellowship of the Research Foundation – Flanders (grant no: 1240220 N). The University of Antwerp received payment for participation of SVK in an Advisory Board of Novosanis (Subsidiary of OraSure Technologies Inc, Wijnegem, Belgium). All funds are handled and managed by the University of Antwerp. LWG and AH: Have outside this project, received free-of-charge test kits from Roche Diagnostics and AH has received honoraria fee from Exeltis. PN, PB, KOB, and CB: No competing interests. AV: is co-founder of and former board member of Novosanis (Subsidiary of OraSure Technologies Inc, Wijnegem, Belgium), a spin-off company of the University of Antwerp, and was minority shareholder until January 2019.